Indication: 1. Prevent and treat rejection or graft-versus-host reaction of allogeneic organ transplantation or bone marrow transplantation. 2. Treat autoimmune diseases such as lupus nephritis and refractory nephrotic syndrome that have not been effectively treated with other immunosuppressants.

Indication: This product can be used to treat moderate to severe infections caused by the above-mentioned sensitive bacteria in adults and children aged 2 months to 16 years, including lower respiratory tract infections (pneumonia and bronchitis), simple lower urinary tract infections and complicated urinary tract infections (including pyelonephritis), uncomplicated skin and skin and soft tissue infections, complicated intra-abdominal infections (including peritonitis and biliary tract infections), obstetric and gynecological infections, sepsis, and empirical treatment of patients with neutropenia and fever. It can also be used for bacterial cerebrospinal meningitis in children. Bacterial culture and drug sensitivity testing should be performed when bacterial infection is suspected, but because cefepime is a broad-spectrum bactericidal agent for gram-positive and gram-negative bacteria, cefepime monotherapy can be started before the results of drug sensitivity tests are known. For suspected mixed anaerobic infections, it is recommended to use other anti-anaerobic drugs, such as metronidazole, for initial treatment. Once the results of bacterial culture and drug sensitivity tests are known, the treatment plan should be adjusted in a timely manner.

Indication: This product can be used to treat moderate to severe infections caused by the above-mentioned sensitive bacteria in adults and children aged 2 months to 16 years, including lower respiratory tract infections (pneumonia and bronchitis), simple lower urinary tract infections and complicated urinary tract infections (including pyelonephritis), uncomplicated skin and skin and soft tissue infections, complicated intra-abdominal infections (including peritonitis and biliary tract infections), obstetrics and gynecology infections, sepsis, and empirical treatment of patients with neutropenia and fever. It can also be used for bacterial cerebrospinal meningitis in children. Bacterial culture and drug sensitivity testing should be performed when bacterial infection is suspected, but because cefepime is a broad-spectrum bactericidal agent for Gram-positive and Gram-negative bacteria, cefepime monotherapy can be started before the results of drug sensitivity tests are known. When mixed anaerobic infections are suspected, it is recommended to use other anti-anaerobic drugs in combination.

Indication: This product can be used to treat moderate to severe infections caused by the above-mentioned sensitive bacteria in adults and children aged 2 months to 16 years, including lower respiratory tract infections (pneumonia and bronchitis), simple lower urinary tract infections and complicated urinary tract infections (including pyelonephritis), uncomplicated skin and skin and soft tissue infections, complicated intra-abdominal infections (including peritonitis and biliary tract infections), obstetrics and gynecology infections, sepsis, and empirical treatment of patients with neutropenia and fever. It can also be used for bacterial cerebrospinal meningitis in children. Bacterial culture and drug sensitivity testing should be performed when bacterial infection is suspected, but because cefepime is a broad-spectrum bactericidal agent for Gram-positive and Gram-negative bacteria, cefepime monotherapy can be started before the results of drug sensitivity tests are known. When mixed anaerobic infections are suspected, it is recommended to use other anti-anaerobic drugs in combination.

Indication: This product can be used to treat moderate to severe infections caused by the above-mentioned sensitive bacteria in adults and children aged 2 months to 16 years, including lower respiratory tract infections (pneumonia and bronchitis), simple lower urinary tract infections and complicated urinary tract infections (including pyelonephritis), uncomplicated skin and skin and soft tissue infections, complicated intra-abdominal infections (including peritonitis and biliary tract infections), obstetrics and gynecology infections, sepsis, and empirical treatment of patients with neutropenia and fever. It can also be used for bacterial cerebrospinal meningitis in children. Bacterial culture and drug sensitivity testing should be performed when bacterial infection is suspected, but because cefepime is a broad-spectrum bactericidal agent for Gram-positive and Gram-negative bacteria, cefepime monotherapy can be started before the results of drug sensitivity tests are known. When mixed anaerobic infections are suspected, it is recommended to use other anti-anaerobic drugs in combination.

Indication: This product can be used to treat moderate to severe infections caused by the above-mentioned sensitive bacteria in adults and children aged 2 months to 16 years, including lower respiratory tract infections (pneumonia and bronchitis), simple lower urinary tract infections and complicated urinary tract infections (including pyelonephritis), uncomplicated skin and skin and soft tissue infections, complicated intra-abdominal infections (including peritonitis and biliary tract infections), obstetrics and gynecology infections, sepsis, and empirical treatment of patients with neutropenia and fever. It can also be used for bacterial cerebrospinal meningitis in children. Bacterial culture and drug sensitivity testing should be performed when bacterial infection is suspected, but because cefepime is a broad-spectrum bactericidal agent for Gram-positive and Gram-negative bacteria, cefepime monotherapy can be started before the results of drug sensitivity tests are known. When mixed anaerobic infections are suspected, it is recommended to use other anti-anaerobic drugs in combination.

Indication: This product can be used to treat moderate to severe infections caused by the above-mentioned sensitive bacteria in adults and children aged 2 months to 16 years, including lower respiratory tract infections (pneumonia and bronchitis), simple lower urinary tract infections and complicated urinary tract infections (including pyelonephritis), uncomplicated skin and skin and soft tissue infections, complicated intra-abdominal infections (including peritonitis and biliary tract infections), obstetrics and gynecology infections, sepsis, and empirical treatment of patients with neutropenia and fever. It can also be used for bacterial cerebrospinal meningitis in children. Bacterial culture and drug sensitivity testing should be performed when bacterial infection is suspected, but because cefepime is a broad-spectrum bactericidal agent for Gram-positive and Gram-negative bacteria, cefepime monotherapy can be started before the results of drug sensitivity tests are known. When mixed anaerobic infections are suspected, it is recommended to use other anti-anaerobic drugs in combination.

Indication: This product can be used to treat moderate to severe infections caused by the above-mentioned sensitive bacteria in adults and children aged 2 months to 16 years, including lower respiratory tract infections (pneumonia and bronchitis), simple lower urinary tract infections and complicated urinary tract infections (including pyelonephritis), uncomplicated skin and skin and soft tissue infections, complicated intra-abdominal infections (including peritonitis and biliary tract infections), obstetrics and gynecology infections, sepsis, and empirical treatment of patients with neutropenia and fever. It can also be used for bacterial cerebrospinal meningitis in children. Bacterial culture and drug sensitivity testing should be performed when bacterial infection is suspected, but because cefepime is a broad-spectrum bactericidal agent for Gram-positive and Gram-negative bacteria, cefepime monotherapy can be started before the results of drug sensitivity tests are known. When mixed anaerobic infections are suspected, it is recommended to use other anti-anaerobic drugs in combination.

Indication: This product can be used to treat moderate to severe infections caused by the above-mentioned sensitive bacteria in adults and children aged 2 months to 16 years, including lower respiratory tract infections (pneumonia and bronchitis), simple lower urinary tract infections and complicated urinary tract infections (including pyelonephritis), uncomplicated skin and skin and soft tissue infections, complicated intra-abdominal infections (including peritonitis and biliary tract infections), obstetrics and gynecology infections, sepsis, and empirical treatment of patients with neutropenia and fever. It can also be used for bacterial cerebrospinal meningitis in children. Bacterial culture and drug sensitivity testing should be performed when bacterial infection is suspected, but because cefepime is a broad-spectrum bactericidal agent for Gram-positive and Gram-negative bacteria, cefepime monotherapy can be started before the results of drug sensitivity tests are known. When mixed anaerobic infections are suspected, it is recommended to use other anti-anaerobic drugs in combination.

Indication: This product can be used to treat moderate to severe infections caused by the above-mentioned sensitive bacteria in adults and children aged 2 months to 16 years, including lower respiratory tract infections (pneumonia and bronchitis), simple lower urinary tract infections and complicated urinary tract infections (including pyelonephritis), uncomplicated skin and skin and soft tissue infections, complicated intra-abdominal infections (including peritonitis and biliary tract infections), obstetrics and gynecology infections, sepsis, and empirical treatment of patients with neutropenia and fever. It can also be used for bacterial cerebrospinal meningitis in children. Bacterial culture and drug sensitivity testing should be performed when bacterial infection is suspected, but because cefepime is a broad-spectrum bactericidal agent for Gram-positive and Gram-negative bacteria, cefepime monotherapy can be started before the results of drug sensitivity tests are known. When mixed anaerobic infections are suspected, it is recommended to use other anti-anaerobic drugs in combination.